Active, Not Recruiting
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT05507541
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +36 more
- Locations
-
- University of Iowa Iowa City, Iowa, United States
- Mayo Clinic Rochester, Minnesota, United States